Anterior Segment

As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchOPHTHALMOLOGY. From thought-provoking expert interviews and peer-reviewed research, to dynamic conference coverage and an expanding portfolio of medical education, this year has been ...

Specializing in ophthalmology is an exciting milestone – but it can also feel overwhelming. The transition from training to independent practice comes with big decisions, new responsibilities and the pressure to build a career that will stand the test of time. We asked members of our faculty and Future Leaders what guidance they would offer to colleagues just beginning their careers.

In this Q&A, Dr Emilio Torres-Neto discusses ELZA-PACE—the second-generation customised cross-linking technique designed to concentrate treatment precisely where the cornea is weakest—alongside the latest insights from the sub400 protocol for ultra-thin corneas and the role of ECO-CAIRS within a staged, individualised rehabilitation pathway.

The US FDA has approved a new topical therapy for keratoconus, marking the first corneal cross-linking treatment that does not require surgical removal of the corneal epithelium. The approval, announced by Glaukos Corporation, addresses a significant gap in treatment options for this progressive and often underdiagnosed rare disease.

In this Q&A, Prof. Alpins reflects on today’s clinical challenges, recent developments and the potential impact of artificial intelligence on the future of eye care.

In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.

With the second half of 2025 underway, we asked our  touchOPHTHALMOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight four exciting areas that look set to change practice - not only as the year draws to a close, but well into the future.

Cloudbreak Pharma has announced positive topline results from its phase II trial of CBT‑004, a novel ophthalmic eye drop designed to treat vascularized pinguecula.

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.